Stock 002826 TIBET AIM PHARM. INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tibet AIM Pharm. Inc.

Equities

002826

CNE100002C39

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
8.91 CNY +0.34% Intraday chart for Tibet AIM Pharm. Inc. +16.93% -24.94%
04-26 Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2023 CI
04-25 Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,939 1,953 1,872 2,094 1,943 2,263
Enterprise Value (EV) 1 1,740 1,833 1,706 1,911 1,672 1,888
P/E ratio 78.6 x 51.4 x 45.1 x 49.8 x 44.3 x 148 x
Yield 0.29% 0.4% 0.82% 0.91% 0.98% -
Capitalization / Revenue 3.97 x 3.53 x 3.11 x 2.89 x 2.27 x 3.39 x
EV / Revenue 3.56 x 3.31 x 2.83 x 2.63 x 1.95 x 2.83 x
EV / EBITDA 58 x 33.1 x 30.7 x 29.4 x 24.3 x 34.1 x
EV / FCF -21.2 x -17.7 x 45.9 x 148 x 18.9 x 13.4 x
FCF Yield -4.72% -5.65% 2.18% 0.67% 5.28% 7.44%
Price to Book 3.14 x 3 x 2.72 x 2.92 x 2.61 x 3.47 x
Nbr of stocks (in thousands) 189,720 193,210 191,769 191,190 190,682 190,678
Reference price 2 10.22 10.11 9.760 10.95 10.19 11.87
Announcement Date 19-04-23 20-04-27 21-04-27 22-04-21 23-04-26 24-04-25
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 488.8 553.3 602.6 725.5 856.7 667
EBITDA 1 30 55.39 55.66 64.95 68.77 55.45
EBIT 1 20.71 44.77 39.2 41.58 46.32 31.32
Operating Margin 4.24% 8.09% 6.51% 5.73% 5.41% 4.69%
Earnings before Tax (EBT) 1 28.99 47.74 47.35 50.01 56.7 23.6
Net income 1 25.26 37.33 41.09 42.48 44.14 15.39
Net margin 5.17% 6.75% 6.82% 5.86% 5.15% 2.31%
EPS 2 0.1300 0.1968 0.2163 0.2200 0.2300 0.0800
Free Cash Flow 1 -82.09 -103.5 37.14 12.88 88.29 140.4
FCF margin -16.79% -18.71% 6.16% 1.78% 10.31% 21.05%
FCF Conversion (EBITDA) - - 66.72% 19.83% 128.39% 253.25%
FCF Conversion (Net income) - - 90.37% 30.32% 200.05% 912.69%
Dividend per Share 2 0.0300 0.0400 0.0800 0.1000 0.1000 -
Announcement Date 19-04-23 20-04-27 21-04-27 22-04-21 23-04-26 24-04-25
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 199 120 165 183 271 375
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -82.1 -103 37.1 12.9 88.3 140
ROE (net income / shareholders' equity) 4.13% 5.88% 6.14% 6.18% 6.27% 2.1%
ROA (Net income/ Total Assets) 1.74% 3.51% 2.81% 3% 3.14% 2.01%
Assets 1 1,455 1,063 1,462 1,416 1,405 764.9
Book Value Per Share 2 3.260 3.380 3.580 3.750 3.910 3.420
Cash Flow per Share 2 1.260 0.8300 1.070 0.9600 1.680 1.770
Capex 1 67.7 170 38.4 25.2 3.2 3.18
Capex / Sales 13.85% 30.81% 6.38% 3.47% 0.37% 0.48%
Announcement Date 19-04-23 20-04-27 21-04-27 22-04-21 23-04-26 24-04-25
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIBET AIM PHARM. INC. Stock Tibet AIM Pharm. Inc.
-24.94% 235M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002826 Stock
  4. Financials Tibet AIM Pharm. Inc.